Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5941 - Lenvatinib and Pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Christine Dierks

Citation

Annals of Oncology (2018) 29 (suppl_8): viii645-viii648. 10.1093/annonc/mdy302

Authors

C. Dierks1, C. Miething1, O. Thomusch2, N. von Bubnoff1, J. Duyster1

Author affiliations

  • 1 Haematology Oncology, University Medical Center Freiburg, 79106 - Freiburg/DE
  • 2 Surgery, University Medical Center Freiburg, 79106 - Freiburg/DE
More

Resources

Abstract 5941

Background

Introduction: Anaplastic thyroid carcinomas (ATC) and metastasized PDTC have a dismal prognosis of only few months despite extensive multimodal therapy. The tumors are high-proliferative and aquire numerous somatic mutations (often over several hundred mutations). These specifics implicate a special sensitivity of the tumors towards anti-angiogenic therapies and immune checkpoint inhibitors.

Methods

In the presented cases, we have combined anti-angiogenic therapy with lenvatinib and the immune checkpoint inhibitor pembrolizumab in 8 patients with metastasized ATC (n = 6) or metastasized PDTC (n = 2). All patient tumors had more than 100 somatic mutations as identified by whole exome sequencing (WES) and PD-L1 > 1%. Lenvatinib was started at 24 mg/kg BW and reduced to minimally 14 mg/kg BW upon appearance of intolerable side effects (uncontrollably high blood pressure, weight loss, loss of appetite). Pembrolizumab was started 3 - 8 weeks later and was given at a fixed dose of 200 mg every 3 weeks. Maximum treatment duration with this combination was 27 months (27, 24, 19, 11, 7, 6, 3, 1 month) and 6 patients are still on therapy.

Results

No continuous °III/IV toxicities were seen with the combination treatment. Weight loss (3 pts) and uncontrollably high blood pressure (3 pts) were normalized after reducing lenvatinib doses. One patient died 5 days after the first dose of pembrolizumab due to disease progression of the cervical tumor. All other patients have reached at least a SD (n = 2), most patients had reached a PR (n = 4) and one patient has reached a complete remission (CR). The majority of patients is still on therapy (27,24,19,7,6 and 3 months), implicating this treatment combination as a safe and effective treatment regimen for this extremely bad prognostic patient cohort.

Conclusions

Our results implicate that a combination of lenvatinib and pembrolizumab is safe and effective in patients with ATC or PDTC. The combination treatment shall now be systematically examined in a phase II clinical trial (ATLEP) in ATC/PDTC patients.

Clinical trial identification

Legal entity responsible for the study

Uniklinik Freiburg.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings